Cabinet Approves Phase III of Biomedical Research Career Programme

On 1 October 2025, the Union Cabinet, chaired by the Prime Minister, approved Phase III of the Biomedical Research Career Programme (BRCP). This continuation builds on earlier phases implemented by the Department of Biotechnology (DBT) and the Wellcome Trust (WT), UK, via the India Alliance. The programme aims to nurture India’s biomedical research capacity, promote translational innovation, and address regional imbalances in scientific infrastructure. Phase III spans 2025‑26 to 2030‑31, with provisions to service approved fellowships and grants until 2037‑38. The total outlay is ₹1,500 crore, with DBT contributing ₹1,000 crore and WT contributing ₹500 crore.

Objectives and Vision

The BRCP Phase III is designed to,

• Support early‑career and intermediate research fellowships in basic, clinical, and public health domains
• Fund collaborative grants, such as Career Development Grants and Catalytic Collaborative Grants involving teams of 2–3 investigators
• Establish a strong Research Management Programme to improve institutional systems, mentoring, networking, public engagement, and partnerships
• Strengthen capacity across Tier‑2 and Tier‑3 regions, reducing geographical disparities
• Promote gender equity, aiming for a 10–15% uplift in support for women researchers
• Enable 25–30% of collaborative programmes to reach at least TRL‑4 (Technology Readiness Level 4 and above)
• Train over 2,000 students and postdoctoral fellows, generate high‑impact publications, and support patentable discoveries

These interventions are meant to elevate India’s position in global biomedical science, and to ensure that national priorities—like healthcare innovation, disease diagnostics, and public health—are well supported by an expanding scientific base.

Significance and Strategic Impact

• Infrastructure & Excellence: Phase I and II laid the groundwork for India as an emerging hub in biomedical sciences. Phase III aims to transform that into international parity in research excellence.
• Translational Emphasis: Moving beyond pure research, this phase focuses on translating findings into deployable technologies, health solutions, and innovations with social impact.
• Institutional Strengthening: By bolstering research management, networking, and mentorship, the programme seeks to build sustainable systems rather than only funding projects.
• Equity & Inclusion: With explicit attention to underrepresented regions and women scientists, the scheme aims for a more distributed growth of research capacity.
• Global Collaboration: Continued partnership with the Wellcome Trust and new international alliances will help Indian researchers connect to global networks.

Challenges to Monitor

• Ensuring timely release and absorption of funds across states and institutions
• Building infrastructure in regions with limited scientific facilities
• Attracting and retaining talent in less-developed areas
• Ensuring accountability, evaluation, and peer review standards remain high
• Translating research into impact while maintaining academic freedom

Static Facts

• The Biomedical Research Career Programme (BRCP) was first launched in 2008‑09 (Phase I), and Phase II began around 2018‑19.
• Phase III duration: 2025‑26 to 2030‑31, with grants serviced till 2037‑38.
• Total budget: ₹1,500 crore (DBT: ₹1,000 crore, Wellcome Trust: ₹500 crore).
• Expected beneficiaries: Over 2,000 students and postdoctoral fellows.
• Target: 10–15% increase in support for women researchers.
• Aim: 25–30% of collaborative programmes reaching TRL‑4+ (technology readiness).
• Key grant types: Early Career Fellowships, Intermediate Fellowships, Career Development Grants, Catalytic Collaborative Grants, and Research Management Programme.